Questran and Hepatic encephalopathy - a phase IV clinical study of FDA data
Hepatic encephalopathy is found among people who take Questran, especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Questran and have Hepatic encephalopathy. It is created by eHealthMe based on reports of 4,050 people who have side effects when taking Questran from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
4,050 people reported to have side effects when taking Questran.
Among them, 54 people (1.33%) have Hepatic encephalopathy.
What is Questran?
Questran has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 4,130 Questran users for its effectiveness, alternative drugs and more.
What is Hepatic encephalopathy?
Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure) is found to be associated with 1,616 drugs and 1,169 conditions by eHealthMe.
Number of Questran and Hepatic encephalopathy reports submitted per year:
Time on Questran when people have Hepatic encephalopathy *:
- < 1 month: 4.55 %
- 1 - 6 months: 95.45 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Hepatic encephalopathy when taking Questran *:
- female: 7.55 %
- male: 92.45 %
Age of people who have Hepatic encephalopathy when taking Questran *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 1.89 %
- 40-49: 1.89 %
- 50-59: 11.32 %
- 60+: 84.91 %
Common drugs people take besides Questran *:
- Lovenox: 44 people, 81.48%
- Ultravist: 44 people, 81.48%
- Cubicin: 44 people, 81.48%
- Lantus: 43 people, 79.63%
- Polaramine: 43 people, 79.63%
- Rifadin: 39 people, 72.22%
- Pantoprazole: 38 people, 70.37%
- Duphalac: 35 people, 64.81%
- Piperacillin And Tazobactam: 24 people, 44.44%
- Symbicort: 23 people, 42.59%
Common side effects people have besides Hepatic encephalopathy *:
- Hyperammonaemia: 47 people, 87.04%
- Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 47 people, 87.04%
- Breathing Difficulty: 46 people, 85.19%
- Diffuse Alveolar Damage (common manifestation of drug-induced lung injury): 44 people, 81.48%
- Rectal Haemorrhage (bleeding from anus): 43 people, 79.63%
- Glomerular Filtration Rate Decreased: 43 people, 79.63%
- Agitation (state of anxiety or nervous excitement): 43 people, 79.63%
- Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 43 people, 79.63%
- Eosinophilic Pneumonia (eosinophil accumulates in the lung): 43 people, 79.63%
- Generalised Oedema (swelling all over the body): 43 people, 79.63%
Common conditions people have *:
- Skin Infection: 44 people, 81.48%
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 5.56%
- Hepatitis C: 2 people, 3.70%
- Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 3.70%
- Urinary Incontinence (inability to control the flow of urine and involuntary urination): 1 person, 1.85%
- Hiv Infection: 1 person, 1.85%
- Gallbladder Disorder: 1 person, 1.85%
- Alcoholic Psychosis: 1 person, 1.85%
* Approximation only. Some reports may have incomplete information.
Do you take Questran and have Hepatic encephalopathy?Check whether Hepatic encephalopathy is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Hepatic encephalopathy and when was it recovered:
Expand to all the drugs that have ingredients of cholestyramine:
Alternative drugs to, pros and cons of Questran:
- Questran (4,130 reports)
Common Questran side effects:
Browse all side effects of Questran:a b c d e f g h i j k l m n o p q r s t u v w x y z
Hepatic encephalopathy treatments and more:
- Hepatic encephalopathy (14,014 reports)
COVID vaccines that are related to Hepatic encephalopathy:
- Hepatic encephalopathy in Moderna COVID Vaccine
- Hepatic encephalopathy in Pfizer BioNTech Covid Vaccine
- Hepatic encephalopathy in Johnson and Johnson Covid Vaccine
Common drugs associated with Hepatic encephalopathy:
All the drugs that are associated with Hepatic encephalopathy:
- Hepatic encephalopathy (1,616 drugs)
Common conditions associated with Hepatic encephalopathy:
All the conditions that are associated with Hepatic encephalopathy:
- Hepatic encephalopathy (1,169 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on cholestyramine (the active ingredients of Questran) and Questran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Xyzal and Heart Disease Aggravated - 7 seconds ago
- Rifampin and Zytiga drug interaction - 9 seconds ago
- Acetaminophen and Electrocardiogram T Wave Abnormal - 11 seconds ago
- Plavix and Femoral Artery Aneurysm - 16 seconds ago
- Angiomyolipoma and Paranasal Sinus Hypersecretion - 21 seconds ago
- Rocephin and Vomiting Projectile - 42 seconds ago
- Propecia and Meningococcal Sepsis - a minute ago
- Excedrin and Tumor Lysis Syndrome - a minute ago
- Zinc Sulfate and Sore Throat - a minute ago
- Nicotine and Loss Of Consciousness - a minute ago